Oppenheimer Asset Management Inc. lifted its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 20.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 249,468 shares of the company's stock after purchasing an additional 42,361 shares during the quarter. Oppenheimer Asset Management Inc.'s holdings in Genmab A/S were worth $4,885,000 at the end of the most recent reporting period.
Several other large investors have also recently made changes to their positions in the company. Marotta Asset Management increased its holdings in shares of Genmab A/S by 5.8% in the first quarter. Marotta Asset Management now owns 13,532 shares of the company's stock worth $265,000 after purchasing an additional 739 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares during the last quarter. Lindbrook Capital LLC grew its position in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares in the last quarter. Grandfield & Dodd LLC increased its stake in Genmab A/S by 4.2% during the fourth quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company's stock worth $704,000 after acquiring an additional 1,370 shares during the last quarter. Finally, Laird Norton Wetherby Wealth Management LLC increased its stake in Genmab A/S by 17.3% during the fourth quarter. Laird Norton Wetherby Wealth Management LLC now owns 13,711 shares of the company's stock worth $286,000 after acquiring an additional 2,023 shares during the last quarter. 7.07% of the stock is owned by institutional investors.
Genmab A/S Price Performance
Shares of NASDAQ:GMAB opened at $20.74 on Wednesday. Genmab A/S Sponsored ADR has a 1 year low of $17.24 and a 1 year high of $28.56. The business has a 50 day simple moving average of $20.94 and a two-hundred day simple moving average of $20.73. The firm has a market capitalization of $13.30 billion, a PE ratio of 11.78, a price-to-earnings-growth ratio of 6.82 and a beta of 0.96.
Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $715.00 million during the quarter, compared to analyst estimates of $5.17 billion. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. Equities research analysts expect that Genmab A/S Sponsored ADR will post 1.45 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on GMAB shares. HC Wainwright reissued a "buy" rating and set a $37.00 price objective (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Truist Financial reduced their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Finally, Wall Street Zen cut Genmab A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $39.17.
Get Our Latest Analysis on GMAB
About Genmab A/S
(
Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
